Synagis®: The Thrive Network helps spread the word about RSV protection

Through the Thrive Network, MedImmune has been helping parents and caregivers speak up and spread the word about RSV protection since 2003. RSV is the leading cause of hospitalization in babies under one year of age. But so many people have never heard of RSV or how serious it can be. Thrive parents want to change that.

How you can help
The easiest way to get involved is to share your story. Your experience with RSV or RSV protection will help other parents know they're not alone. Your insights will also help Thrive and MedImmune understand what kind of support parents might need.

Becoming a Thrive advocate
After speaking with a Thrive representative, you may have the chance to become a Thrive advocate. Some of our advocates have shared their stories with doctors, nurses and even people working to change healthcare policies.

So if you're passionate about raising RSV awareness, start by sharing your story with us. Together, we can help make sure parents across the country are ready for RSV season.

Share your story with the Thrive community.

Questions? You can reach us at 1-866-378-9600 or info@Thrive-Network.com.

How is Thrive funded?
The Thrive Network is exclusively funded by MedImmune and operated by Health Advocacy Strategies at MedImmune's direction.

Will I get paid to participate?
No, all of our activities are completely voluntary. Thrive members choose when and how they'd like to participate.

I know someone who might be interested in joining. How can they learn more?
Send friends and family an e-card inviting them to read about Thrive.

Important Safety Information

Synagis® (palivizumab) is indicated for the prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Synagis is given as a shot, usually in the thigh muscle, each month during the RSV season. The first dose of Synagis should be given before RSV season begins. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis has been used in more than one million children in the U.S. since its introduction in 1998.

Very rare cases (<1 per 100,000 patients) of severe allergic reactions such as anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. These rare reactions may occur when any dose of Synagis is given, not just the first one. Also, rare but serious side effects can occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Other side effects with Synagis may include upper respiratory tract infection, ear infection, fever, and runny nose. In children born with heart problems, Synagis was associated with reports of low blood oxygen levels and abnormal heart rhythms. Synagis should not be used in patients with a history of a severe prior reaction to Synagis or its components. Side effects, such as, skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort) can also occur.